Bakakos Agamemnon, Bakakos Petros, Rovina Nikoletta
Department of Respiratory Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
J Pers Med. 2021 Dec 16;11(12):1374. doi: 10.3390/jpm11121374.
Viral infections are one of the main causes of asthma exacerbations. During the COVID-19 era, concerns regarding the relationship of SARS-CoV2 with asthma have been raised. The concerns are both for COVID severity and asthma exacerbations. Many studies on COVID-19 epidemiology and comorbidities have assessed whether asthma represents a risk factor for SARS-CoV2 infection and/or more severe course of the disease. This review covers the current evidence on the prevalence of asthma in COVID-19 and its association with susceptibility to and severity of SARS-CoV2 infection. It will examine the possible role of underlying asthma severity in COVID-19 related outcomes as well as the molecular mechanisms involved in the co-existence of these entities. The possible role of asthma inflammatory phenotypes will also be evaluated. Finally, the impact of asthma comorbidities and the implications of asthma medication on COVID-19 will be addressed.
病毒感染是哮喘急性加重的主要原因之一。在新冠疫情期间，人们对严重急性呼吸综合征冠状病毒2（SARS-CoV2）与哮喘之间的关系提出了担忧。这些担忧既涉及新冠病情的严重程度，也关乎哮喘的急性加重。许多关于新冠流行病学和合并症的研究评估了哮喘是否是SARS-CoV2感染和/或该疾病更严重病程的危险因素。本综述涵盖了关于新冠患者中哮喘患病率及其与SARS-CoV2感染易感性和严重程度之间关联的现有证据。它将研究潜在哮喘严重程度在新冠相关结局中的可能作用，以及这些情况并存时所涉及的分子机制。哮喘炎症表型的可能作用也将得到评估。最后，将探讨哮喘合并症的影响以及哮喘药物对新冠的影响。
